Trifarotene


Generic Medicine Info
Indications and Dosage
Topical/Cutaneous
Acne vulgaris
Adult: In cases when many comedones, papules and pustules are present: As 50 mcg/g cream: Apply thinly onto affected areas of the face and/or trunk once daily in the evening, on clean and dry skin. Use of 1-4 pumps may be necessary: 1 pump actuation should cover the face (e.g. forehead, nose, cheeks, chin); 2 pump actuations should cover the upper trunk (e.g. reachable upper back, shoulders and chest); 1 additional pump actuation for middle and lower back if needed. Reassess the patient after 3 months of treatment. Treatment duration may vary according to clinical response.
Child: ≥9 years or ≥12 years As 50 mcg/g cream: Same as adult dose. Starting age for child dosing may vary between countries (refer to specific product guidelines).
Contraindications
Pregnancy or women planning a pregnancy.
Special Precautions
Patient with eczema. Children. Lactation.
Adverse Reactions
Significant: Local skin reactions (e.g. erythema, scaling, dryness, stinging or burning sensation); photosensitivity.
Skin and subcutaneous tissue disorders: Sunburn, allergic dermatitis.
Patient Counseling Information
Use moisturiser as frequently as needed. Avoid application to cuts, abrasions, eczematous or sunburned skin. Avoid wax depilation on treated skin, or contact with eyes, eyelids, lips or mucous membranes. Avoid excessive exposure to sunlight or sunlamps; wear sunscreen or protective clothing over treated areas when going outdoors.
Drug Interactions
May cause additive irritant effects with cosmetics or other acne medications that have drying, irritant or desquamative effects.
Action
Description:
Mechanism of Action: Trifarotene, a terphenyl acid derivative, is a retinoic acid receptor (RAR) agonist with greater selectivity at the gamma (γ) subtype of RAR. It modulates retinoid target genes which are associated with cell differentiation and mediation of inflammation.
Pharmacokinetics:
Distribution: Plasma protein binding: Approx 99.9%.
Metabolism: Primarily metabolised by CYP2C9, CYP3A4 and CYP2C8.
Excretion: Via faeces. Terminal elimination half-life: 2-9 hours.
Chemical Structure

Chemical Structure Image
Trifarotene

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 11518241, Trifarotene. https://pubchem.ncbi.nlm.nih.gov/compound/Trifarotene. Accessed Jan. 25, 2024.

Storage
Store between 15-30°C. Protect from heat.
MIMS Class
Acne Treatment Preparations
ATC Classification
D10AD06 - trifarotene ; Belongs to the class of topical retinoid preparations. Used in the treatment of acne.
References
Aklief 50 mcg/g Cream (Galderma Philippines, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 11/10/2023.

Aklief 50 microgram/g Cream (Galderma [UK] Limited). MHRA. https://products.mhra.gov.uk. Accessed 11/10/2023.

Aklief 50 microgram/g Cream (Galderma Hong Kong Ltd). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 12/01/2024.

Aklief Cream (Galderma Laboratories, L.P.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 11/10/2023.

Anon. Trifarotene. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 11/10/2023.

Anon. Trifarotene. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/10/2023.

Buckingham R (ed). Trifarotene. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/10/2023.

Joint Formulary Committee. Trifarotene. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/10/2023.

Disclaimer: This information is independently developed by MIMS based on Trifarotene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in